Alpelisib; BYL719; BYL-719
$500.00
CAS No.: 1217486-61-7
Catalog No.: 100803
Purity: 95%
MF: C19H22F3N5O2S
MW: 441.479
Storage: 2-8 degree Celsius
SMILES: CC1=C(SC(NC(=O)N2CCC[C@H]2C(N)=O)=N1)C1=CC(=NC=C1)C(C)(C)C(F)(F)F
Catalog No.: 100803
Purity: 95%
MF: C19H22F3N5O2S
MW: 441.479
Storage: 2-8 degree Celsius
SMILES: CC1=C(SC(NC(=O)N2CCC[C@H]2C(N)=O)=N1)C1=CC(=NC=C1)C(C)(C)C(F)(F)F
CAS NO.: 1217486-61-7; (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide (Alpelisib; BYL719; BYL-719). PROPERTIES: Alpelisib is a crystalline solid with a molecular weight of ~529 g/mol. It is slightly soluble in water but soluble in DMSO, making it suitable for in vitro assays. The compound should be stored at room temperature in a dry, sealed container. As a PI3K inhibitor, it may have low acute toxicity, but handle with care to avoid inhalation or contact with mucous membranes. APPLICATIONS: Alpelisib is a targeted anticancer drug approved for treating hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutations. It selectively inhibits PI3K , blocking the PI3K/AKT/mTOR pathway to suppress tumor cell proliferation. Preclinical studies and clinical trials have validated its efficacy in combination with fulvestrant. This application is detailed in oncology research and FDA regulatory documents for targeted cancer therapies.
Reviews
Write Your Own Review